Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix's new PRX-00023 drug for generalized anxiety disorder is reported to have produced poor results in a phase III clinical trial.
Subscribe to our email newsletter
The drug did not show any improvement in patients compared to placebo and failed to reach the expected results.
Epix suggested the outcome may have been affected by a higher-than-expected response in the placebo-treated patients. Epix also said they would now focus on the benefits of the drug for patients with depression.
“We are disappointed that treatment with PRX-00023 did not induce a statistically significant change in the HAM-A in patients with anxiety; however, we are encouraged by the data and will further analyze these results,” said Michael Kauffman CEO of Epix.
A preliminary review has indicated that PRX-00023 was well tolerated. Side effects, including impact on sexual function and sleep, in patients receiving PRX-00023, were similar to placebo.